Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1219167
- By:
- Publication type:
- Article
Works by Geng, Hongzhi
Results: 12
1
2
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.664421
- By:
- Publication type:
- Article
3
P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R‐CHOP OR R‐CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON‐GERMINAL CENTER B‐CELL SUBTYPE DIFFUSE LARGE B‐CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
- Published in:
- HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000971640.48516.5b
- By:
- Publication type:
- Article
4
PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
- Published in:
- 2023
- By:
- Publication type:
- Abstract
5
Bibliometric and literature review of the development of mineral fertilizers.
- Published in:
- Environmental Science & Pollution Research, 2024, v. 31, n. 1, p. 27, doi. 10.1007/s11356-023-31209-w
- By:
- Publication type:
- Article
6
Distal myopathy due to TCAP variants in four unrelated Chinese patients.
- Published in:
- Neurogenetics, 2021, v. 22, n. 1, p. 1, doi. 10.1007/s10048-020-00623-4
- By:
- Publication type:
- Article
7
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3227
- By:
- Publication type:
- Article
8
Chemical characteristics and evolution of groundwater in northeastern margin of the Tibetan Plateau, China.
- Published in:
- Environmental Geochemistry & Health, 2025, v. 47, n. 1, p. 1, doi. 10.1007/s10653-024-02311-w
- By:
- Publication type:
- Article
9
Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases.
- Published in:
- Oncology Letters, 2025, v. 29, n. 2, p. N.PAG, doi. 10.3892/ol.2024.14817
- By:
- Publication type:
- Article
10
Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway.
- Published in:
- Cardiovascular Drugs & Therapy, 2021, v. 35, n. 6, p. 1129, doi. 10.1007/s10557-020-07018-5
- By:
- Publication type:
- Article
11
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.997589
- By:
- Publication type:
- Article
12
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.858021
- By:
- Publication type:
- Article